Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of
cardiovascular adverse effects. An increased risk of myocardial infarction had been …

Background Selective inhibition of cyclo-oxygenase-2 has been associated with an
increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp …

Background In comparing aspirin, nonselective nonsteroidal antiinflammatory agents
(NSAIDs), and cyclooxygenase (COX)-2 inhibitors, variation in platelet inhibitory effects …

Objectives To examine whether the increased risk of cardiovascular events with rofecoxib
represents a class effect of cyclooxygenase-2 (COX-2) specific inhibitors. Design Systematic …

Cyclo-oxygenase-2 (COX-2) inhibitors appear to alter the balance of vasoactive eicosanoids
(prostacyclin and thromboxane) and to suppress the inflammatory mediators implicated in …

Background: Cyclo-oxygenase-2 selective inhibitors have been associated with
cardiovascular side effects, but previous studies have generally excluded people with …

ContextEvidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny
of other nonsteroidal anti-inflammatory drugs (NSAIDs). Regulatory agencies have provided …

Purpose To evaluate the risk of myocardial infarction (MI) associated with the use of
selective cyclooxygenase‐2 (COX‐2) inhibitors (coxibs). Methods Systematic review and …

Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2
(COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting …

Results of premarketing and postmarketing trials have raised doubts about the
cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID) rofecoxib …